Literature DB >> 18703277

Esophageal adenocarcinoma arising in Barrett esophagus.

Hui Ying Zhang1, Stuart Jon Spechler, Rhonda F Souza.   

Abstract

The major risk factors for esophageal adenocarcinoma are gastroesophageal reflux disease (GERD) and Barrett esophagus, a squamous-to-columnar cell metaplasia that predisposes to malignancy. Adenocarcinomas in Barrett esophagus are thought to arise through a sequence of growth-promoting, genetic alterations that accumulate until the cells have acquired the physiologic hallmarks of cancer proposed by Hanahan and Weinberg. Moreover, GERD and Barrett esophagus are associated with chronic esophagitis, and inflammation is a well known risk factor for cancer formation. The cell that gives rise to Barrett metaplasia is not known. It has been proposed that the metaplasia may arise from a change in the differentiation pattern of stem cells that either reside in the esophagus or are recruited to the esophagus from the bone marrow. Alternatively, it is possible that Barrett metaplasia develops through the conversion of one differentiated cell type into another. Regardless of the cell of origin, Barrett metaplasia ultimately must be sustained by stem cells, which might be identified by intestinal stem cell markers. An emerging concept in tumor biology is that cancer stem cells are responsible for sustaining tumor growth. If Barrett cancers develop from Barrett stem cells, then a therapy targeted at those stem cells might prevent esophageal adenocarcinoma. This report reviews the risk factors for Barrett esophagus and esophageal adenocarcinoma, the mechanisms by which genetic alterations might contribute to carcinogenesis in Barrett esophagus, and the role of stem cells in the development of Barrett metaplasia and adenocarcinoma.

Entities:  

Mesh:

Year:  2008        PMID: 18703277      PMCID: PMC2673195          DOI: 10.1016/j.canlet.2008.07.006

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  71 in total

1.  Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma.

Authors:  Reda S Saad; Yasser El-Gohary; Ellias Memari; Yulin L Liu; Jan F Silverman
Journal:  Hum Pathol       Date:  2005-09       Impact factor: 3.466

2.  Downregulation of TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L in Barrett's esophagus with dysplasia and adenocarcinoma.

Authors:  Nikolay K Popnikolov; Zoran Gatalica; Patrick A Adegboyega; Brent A Norris; P Jay Pasricha
Journal:  Appl Immunohistochem Mol Morphol       Date:  2006-06

Review 3.  To die or not to die: an overview of apoptosis and its role in disease.

Authors:  S W Hetts
Journal:  JAMA       Date:  1998-01-28       Impact factor: 56.272

Review 4.  A survey of telomerase activity in human cancer.

Authors:  J W Shay; S Bacchetti
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

5.  Abdominal obesity and the risk of Barrett's esophagus.

Authors:  Hashem B El-Serag; Peter Kvapil; Joan Hacken-Bitar; Jennifer R Kramer
Journal:  Am J Gastroenterol       Date:  2005-10       Impact factor: 10.864

6.  Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.

Authors:  Uta Reichelt; Peer Duesedau; Maria Ch Tsourlakis; Alexander Quaas; Björn C Link; Paulus G Schurr; Jussuf T Kaifi; Stephanie J Gros; Emre F Yekebas; Andreas Marx; Ronald Simon; Jakob R Izbicki; Guido Sauter
Journal:  Mod Pathol       Date:  2006-11-24       Impact factor: 7.842

Review 7.  Epidemiology and pathogenesis of esophageal cancer.

Authors:  Rebecca S Holmes; Thomas L Vaughan
Journal:  Semin Radiat Oncol       Date:  2007-01       Impact factor: 5.934

Review 8.  Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis.

Authors:  Ai Kubo; Douglas A Corley
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-05       Impact factor: 4.254

9.  Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis.

Authors:  Ok-Jae Lee; Regine Schneider-Stock; Patricia A McChesney; Doerthe Kuester; Albert Roessner; Michael Vieth; Christopher A Moskaluk; Wa'el El-Rifai
Journal:  Neoplasia       Date:  2005-09       Impact factor: 5.715

10.  Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation.

Authors:  T Bailey; L Biddlestone; N Shepherd; H Barr; P Warner; J Jankowski
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

View more
  23 in total

1.  Radiofrequency ablation for dysplasia in Barrett's esophagus restores β-catenin activation within esophageal progenitor cells.

Authors:  K Krishnan; S Komanduri; J Cluley; R Dirisina; P Sinh; Jeff Z Ko; L Li; R B Katzman; T A Barrett
Journal:  Dig Dis Sci       Date:  2011-09-24       Impact factor: 3.199

2.  Introduction: esophagus, dysplasia, and early esophageal adenocarcinoma: managing the transition.

Authors:  George A Sarosi
Journal:  J Gastrointest Surg       Date:  2010-02-17       Impact factor: 3.452

3.  Expression of Gastric Markers Is Associated with Malignant Potential of Nonampullary Duodenal Adenocarcinoma.

Authors:  Chihiro Minatsuki; Nobutake Yamamichi; Ken-Ichi Inada; Yu Takahashi; Kouhei Sakurai; Takeshi Shimamoto; Yosuke Tsuji; Kazuya Shiogama; Shinya Kodashima; Yoshiki Sakaguchi; Keiko Niimi; Satoshi Ono; Toru Niwa; Ken Ohata; Nobuyuki Matsuhashi; Masao Ichinose; Mitsuhiro Fujishiro; Yutaka Tsutsumi; Kazuhiko Koike
Journal:  Dig Dis Sci       Date:  2018-06-28       Impact factor: 3.199

Review 4.  Connection between inflammation and carcinogenesis in gastrointestinal tract: focus on TGF-beta signaling.

Authors:  Suntaek Hong; Ho-Jae Lee; Seong Jin Kim; Ki-Baik Hahm
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

Review 5.  Role of nitric oxide in the pathogenesis of Barrett's-associated carcinogenesis.

Authors:  Gen Kusaka; Kaname Uno; Katsunori Iijima; Tooru Shimosegawa
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

Review 6.  Etiology, cancer stem cells and potential diagnostic biomarkers for esophageal cancer.

Authors:  Kuancan Liu; Tingting Zhao; Junkai Wang; Yunyun Chen; Rui Zhang; Xiaopeng Lan; Jianwen Que
Journal:  Cancer Lett       Date:  2019-05-21       Impact factor: 8.679

7.  The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.

Authors:  Alvarez Hector; Elizabeth A Montgomery; Collins Karikari; Marcia Canto; Kerry B Dunbar; Jean S Wang; Georg Feldmann; Seung-Mo Hong; Michael C Haffner; Alan K Meeker; Sacha J Holland; Jiaxin Yu; Thilo J Heckrodt; Jing Zhang; Pingyu Ding; Dane Goff; Rajinder Singh; Juan Carlos Roa; Arivusudar Marimuthu; Gregory J Riggins; James R Eshleman; Barry D Nelkin; Akhilesh Pandey; Anirban Maitra
Journal:  Cancer Biol Ther       Date:  2010-11-15       Impact factor: 4.742

8.  Targeting chemokine pathways in esophageal adenocarcinoma.

Authors:  Makardhwaj S Shrivastava; Zulfiqar Hussain; Orsolya Giricz; Niraj Shenoy; Rahul Polineni; Anirban Maitra; Amit Verma
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 9.  Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer.

Authors:  Linda A Feagins; Rhonda F Souza; Stuart J Spechler
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-05       Impact factor: 46.802

10.  The secretory phospholipase A2 gene is required for gastroesophageal reflux-related changes in murine esophagus.

Authors:  Ashok Babu; David Mauchley; Xianzhong Meng; Anirban M Banerjee; Fabia Gamboni-Robertson; David A Fullerton; Michael J Weyant
Journal:  J Gastrointest Surg       Date:  2009-08-12       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.